Klothea Bio

Klothea Bio is an early-stage biotech pioneering mRNA-based therapies targeting the aging-associated Klotho protein. The company's core technology combines a proprietary, highly effective mRNA construct with novel, safe nanocarriers designed for repeat dosing, differentiating it from conventional mRNA vaccine approaches. With a lead program targeting metabolic syndrome, Klothea is preparing for Phase 1 clinical trials in early 2026 and has established a partnership with the Healthy Longevity clinic, a semifinalist in the XPRIZE Healthspan competition. The company is backed by a world-class Scientific Advisory Board including the discoverer of the Klotho protein, Dr. Makoto Kuro-o.

Proprietary mRNA technology combined with novel, safe nanocarriers (non-LNP) designed for repeat dosing, aimed at enhancing endogenous secretion of the Klotho protein. Also exploring exosome delivery.

The longevity space is competitive with various mechanisms (senolytics, mTOR inhibitors, etc.). Klothea appears to be first with an mRNA approach to Klotho, but may face future competition from other modalities (e.g., gene therapy, small molecules) targeting the same pathway. Its novel delivery system differentiates it from conventional mRNA vaccine companies.